ÂÜÀòÂÒÂ×

Janet Gunzner-Toste, PhD MBA, serves as the Senior Vice President of Operations at Spyre Therapeutics since June 2023, following a tenure as Chief Operating Officer at Exavir Therapeutics. Janet previously held the position of Vice President of Program Management at BridgeBio, where involvement included projects related to Acoramidis and BBP-711, and served as Senior Director of Program and Alliance Management at Nektar Therapeutics, focusing on oncology-related therapies. Janet's extensive background at Genentech included roles as Senior Project Manager and Medicinal Chemistry Team Leader, contributing to diverse therapeutic areas and co-inventing the FDA-approved oncology medicine Erivedge®. Earlier experience at Merck involved advancing small molecule antagonists for neurological disorders. Janet's academic credentials include an MBA from the University of California, Berkeley, a postdoc at Stanford University, a PhD from Scripps Research, and a BA from Reed College.